Age (years), mean±SD | 15.25±4.1 |
Sex, n (%) |
Male | 24 (48) |
Female | 26 (52) |
Weight (kg), mean±SD | 40.6±9.2 |
Height (cm), mean±SD | 146.3±103 |
BMI (kg/m2), mean±SD | 18.8±2.6 |
Disease duration (years), mean±SD | 14.5±2.6 |
Positive family history, n (%) | 40 (80) |
Transfusion index (mL/kg/year) | 126±45(59–222) |
Splenectomised, n (%) |
Yes | 34 (68) |
No | 16 (32) |
Chelation therapy, n (%) |
Combined therapy | 27 (54) |
Mono therapy | 23 (46) |
Compliance to chelation, n (%) |
Good | 28 (56) |
Poor | 22 (44) |
Cardiac complications, n (%) |
Yes | 24 (48) |
No | 26 (52) |
Oral glucose tolerance test, n (%) |
Normal | 20 (40) |
Impaired fasting glucose | 20 (40) |
Overt diabetes | 10 (20) |
Triglyceride (mg/dL), median (IQR) | 154 (134–211) |
Triglyceride index, median (IQR) | 8.13 (6.6–10.62) |
FBG (mg/dL), median (IQR) | 106 (100–143) |
2 h BG (mg/dL), median (IQR) | 130 (121–195) |
ALT (U/L), median (IQR) | 44 (34–66) |
Albumin (mg/dL), median (IQR) | 3.9 (3.5–4.1) |
Ferritin (µg/L), median (IQR) | 2750 (1319–5516) |
Amylase (IU/L), median (IQR) | 63.5 (44–84) |
Lipase (IU/L), median (IQR) | 63 (42–83) |
Cardiac T2* (ms), median (IQR) | 22 (12–31) |
Hepatic T2* (ms), median (IQR) | 5.5 (4–9) |